You've probably heard of the buy-low-and-sell-high investment strategy, but what about buying high and selling even higher?

After sliding throughout most of 2022, shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) jumped nearly 300% higher on Dec. 19, 2022. This is a clinical-stage drugmaker, and investors were cheering for its experimental liver disease treatment after it produced surprisingly good trial results.

Despite blowing through the roof already, there's a good chance that this stock could shoot even higher in 2023. Here's why.

Continue reading

Source Fool.com